NCT06806930View on ClinicalTrials.gov

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIICarcinoma, Breast
Interventions
DRUG

Neoadjuvant endocrine therapy

Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)

DRUG

Neoadjuvant endocrine therapy

Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks

DRUG

Neoadjuvant endocrine therapy

Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks

Trial Locations (1)

20037

RECRUITING

George Washington-Medical Faculty Associates, Washington D.C.

All Listed Sponsors
lead

George Washington University

OTHER